3D LifePrints closes Series A funding round with Fenwall Investments

3D LifePrints (Liverpool, UK) has closed a Series A funding round of £500,000 with Fenwall Investments (Merseyside, UK) to enable accelerated expansion of the company.

Go to the profile of Jasmine Harris
Jan 24, 2018
0
0
Upvote 0 Comment

One of the UK’s leading medical 3D printing companies, 3D LifePrints UK Ltd (Liverpool, UK), has closed a Series A funding round of £500,000 with Fenwall Investments Ltd (Merseyside, UK). The investment is hoped to enable accelerated expansion for the company and follows previous Seed Funding investment in 2016.

3D LifePrints provide a variety of medical 3D printing manufacturing and service capabilities for NHS hospitals and academic institutions, partnering clinicians, healthcare providers and academics. They provide a range of innovative 3D printed products, reducing operational costs and enhancing patient care.

The investment is expected to be utilized by 3D LifePrints to expand their collection of embedded medical 3D printing hubs across the NHS and overseas, recruit 3D technologists and bio-medical engineers and invest in further research and development.

Paul Fotheringham, Founder and Chief Technology Officer of 3D LifePrints, commented: “We are extremely pleased to announce the completion of this funding round which will accelerate our unique model of embedded 3D medical printing services to drive down operational costs, provide innovative 3D technology-based products and services, and ultimately improve patient care.”

“We’re delighted to be on board with this talented team operating in an emerging and fast-developing market. We feel the timing is perfect to allow 3D LifePrints to capitalize on its potential. I’m looking forward to an exciting and profitable partnership,” concluded Andrew Douglas, Managing Director of Fenwall Investments Ltd.


Source:
http://3dlifeprints.com/3dlp-news-funding

Go to the profile of Jasmine Harris

Jasmine Harris

Digital Editor, Future Science Group

No comments yet.